By jurisdiction

United Kingdom (MHRA)

Every compound we track that has a recorded status under United Kingdom (MHRA). Tap a name for the full picture, including the U.S. status and primary sources.

United Kingdom (MHRA): status by compound
CompoundStatus hereNote
BPC-157RestrictedNo UK marketing authorisation; supply for human use treated as an unlicensed medicine.
CagrilintideRestrictedNo UK marketing authorisation; supply for human use treated as an unlicensed medicine.
CJC-1295RestrictedNo UK marketing authorisation; supply for human use treated as an unlicensed medicine.
Emideltide (DSIP)RestrictedNo UK marketing authorisation; supply for human use treated as an unlicensed medicine.
EpitalonRestrictedNo UK marketing authorisation; supply for human use treated as an unlicensed medicine.
GHK-CuRestrictedNo UK marketing authorisation; supply as a medicine is unlicensed, though copper tripeptide-1 remains a permitted cosmetic ingredient under GB cosmetics law.
IpamorelinRestrictedNo UK marketing authorisation; supply for human use treated as an unlicensed medicine.
KPVRestrictedNo UK marketing authorisation; supply for human use treated as an unlicensed medicine.
Melanotan IIRestrictedNo UK marketing authorisation; MHRA has repeatedly removed melanotan products from sale for over 10 years, though nasal sprays without medicinal claims are not generally regulated as medicines.
MOTS-cRestrictedNo UK marketing authorisation; supply for human use treated as an unlicensed medicine.
NAD+RestrictedNo UK marketing authorisation; injectable NAD+ is supplied only as an unlicensed ‘special’ on a prescriber’s order, while oral NAD+ is sold under food-supplement rules.
RetatrutideRestrictedNo UK marketing authorisation; supply for human use treated as an unlicensed medicine - MHRA has seized unlicensed retatrutide products in enforcement operations.
SelankRestrictedNo UK marketing authorisation; supply for human use treated as an unlicensed medicine.
Semaglutide (compounded)RestrictedLicensed prescription-only medicine; unlicensed copies may not be supplied where the licensed product can meet the patient’s need, and MHRA enforces against unlicensed semaglutide products.
SemaxRestrictedNo UK marketing authorisation; supply for human use treated as an unlicensed medicine.
SermorelinRestrictedNo UK marketing authorisation; supply for human use treated as an unlicensed medicine.
TB-500 (Thymosin Beta-4)RestrictedNo UK marketing authorisation; supply for human use treated as an unlicensed medicine.
Thymosin Alpha-1RestrictedNo UK marketing authorisation; supply for human use treated as an unlicensed medicine.
Tirzepatide (compounded)RestrictedLicensed prescription-only medicine; no legitimate compounding pathway; MHRA enforces against unlicensed product.